Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07276542 · ClinicalTrials.gov registry record · Phase 2
Clinical Trial Exploring the Outpatient Treatment of Phantom Limb Pain With Ketamine Administration in a Six Month Study With a Minimum Remission Period of 7 Days Between Treatment Session. 25-30 Subjects With an Ongoing History of Significant PLP.--FDA and IRB Approved.
A Phase 2 study of Phantom Limb Syndrome With Pain, sponsored by The Ketamine Research Foundation.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 4
- Study locations
NCT07276542 is a Phase 2 study of Phantom Limb Syndrome With Pain that is actively recruiting participants, run by The Ketamine Research Foundation. The registered enrollment target is 30 participants. The trial reports 4 study locations across 2 states.
The verdict
NCT07276542, a Phase 2 study of Phantom Limb Syndrome With Pain, is actively recruiting participants, sponsored by The Ketamine Research Foundation.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 4
- Study locations
Study Summary
Must be living Within a 50 mile radius of our study sites: Bay Area, Los Angeles, Albuquerque, Sacramento, Los Angeles An anecdotal report with administration of ketamine in a non-clinical setting providing and sustained remission of symptoms after 6 years has furthered the interest in ascertaining if ketamine might indeed be a successful intervention. (See Wolfson and Barocchi). Ketamine has shown benefit in a variety of pain and neurological disorders. Its exploration for these continues and there appears to be an expanding use of ketamine for difficult to treat syndromes. Phantom limb pain occurs in over 50% of amputees, tends to be immediate in onset, but may occur at a later time. It is often excruciating, with a high frequency of episodes that tend to diminish with time-- variably. Its treatment is reliant on opioids and other pain medications usually with limited results. Acupuncture has been minimally explored with no clear results. Our study aims at clarifying ketamine's status for this particular disorder. This is an off-label use of RS ketamine for clinical purposes. Each subject of the 25-30 enrolled in the study will have up to 16 ketamine sessions over six months time, Subjects will be continued in the study if the partial or complete remission period is seven days or more, If less, subjects will be considered to have not adequately responded to the protocol's provision of IM ketamine. Dosage of ketamine will be determined in the initial session with a dosage escalation protocol with an upper limit of 120mg--that limit not to be exceeded for the duration of each subject's participation in the study.. The time for a succeeding session of ketamine is variable depending on response and therefore the duration of the remission--not to be less than 7 days as the minimum consideration for a response, Subjects will receive support throughout their sessions and these will be conducted with integration following the medication, much as in the ketamine assiste
Conditions Studied
Interventions
- DRUG IM ketamine in dose finding and then continuation
Study Locations (4)
California
- Shamynds - Sacramento
- Ketamine Research Foundation - San Anselmo
- Mystic Health - Santa Monica
New Mexico
- Lisa Feierman MD - Albuquerque
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-01-15 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07276542
The ClinicalTrials.gov registry entry for NCT07276542 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Ketamine Research Foundation, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Phantom Limb Syndrome With Pain appearing as the primary indexed condition, and to 1 intervention - of which IM ketamine in dose finding and then continuation is the first listed.
NCT07276542 reports 4 study locations spanning 2 distinct geographic areas - top geographies include California, New Mexico.
Frequently Asked Questions
What is clinical trial NCT07276542 about?
NCT07276542 is a clinical study titled "Clinical Trial Exploring the Outpatient Treatment of Phantom Limb Pain With Ketamine Administration in a Six Month Study With a Minimum Remission Period of 7 Days Between Treatment Session. 25-30 Subjects With an Ongoing History of Significant PLP.--FDA and IRB Approved.". Must be living Within a 50 mile radius of our study sites: Bay Area, Los Angeles, Albuquerque, Sacramento, Los Angeles An anecdotal report with administration of ketamine in a non-clinical setting providing and sustained remission of symptoms after 6 years has furthered the interest in ascertaining...
What is the current status of trial NCT07276542?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2026-01-15. Estimated completion is 2026-12-31.
What conditions does trial NCT07276542 study?
This clinical trial studies the following conditions: Phantom Limb Syndrome With Pain.
What interventions are being tested in trial NCT07276542?
The interventions under investigation include: IM ketamine in dose finding and then continuation (DRUG).
Who is sponsoring clinical trial NCT07276542?
This trial is sponsored by The Ketamine Research Foundation, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07276542 being conducted?
This trial has 4 study locations across California, New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Phantom Limb Syndrome With Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.